These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3016205)

  • 1. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
    Body JJ; Borkowski A; Cleeren A; Bijvoet OL
    J Clin Oncol; 1986 Aug; 4(8):1177-83. PubMed ID: 3016205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
    Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
    Body JJ; Pot M; Borkowski A; Sculier JP; Klastersky J
    Am J Med; 1987 May; 82(5):957-63. PubMed ID: 3578365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
    Coleman RE; Rubens RD
    Br J Cancer; 1987 Oct; 56(4):465-9. PubMed ID: 3689664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of aminohydroxypropylidene diphosphonate in the treatment of malignancy-associated hypercalcaemia.
    Stevens MJ
    Med J Aust; 1987 Mar; 146(5):261-4. PubMed ID: 3821622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
    Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
    Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
    Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT
    Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.
    Jacobs TP; Siris ES; Bilezikian JP; Baquiran DC; Shane E; Canfield RE
    Ann Intern Med; 1981 Mar; 94(3):312-6. PubMed ID: 6452846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
    Body JJ; Magritte A; Seraj F; Sculier JP; Borkowski A
    J Bone Miner Res; 1989 Dec; 4(6):923-8. PubMed ID: 2692407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aminohydroxypropylidene diphosphonate on the bone metabolism of patients with parathyroid adenoma.
    Ishimura E; Miki T; Koyama H; Harada K; Nakatsuka K; Inaba M; Nishizawa Y; Morii H
    Horm Metab Res; 1993 Sep; 25(9):493-7. PubMed ID: 8225204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
    Yates AJ; Murray RM; Jerums GJ; Martin TJ
    Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
    Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
    J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy.
    Bickerstaff DR; O'Doherty DP; McCloskey EV; Hamdy NA; Mian M; Kanis JA
    Bone; 1991; 12(1):17-20. PubMed ID: 2054231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
    Mannix KA; Carmichael J; Harris AL; Cantwell BM
    Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of refractory cancer-associated hypercalcemia with aminohydroxypropylidene diphosphonate.
    Heaf JG; Hansen M
    Acta Med Scand; 1988; 224(3):287-8. PubMed ID: 3239457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
    Tubiana-Hulin M; de Vernejoul MC; Brière M; Miravet L; Clavel B
    Presse Med; 1984 Feb; 13(8):483-6. PubMed ID: 6230630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia.
    Ostenstad B; Andersen OK
    Acta Oncol; 1992; 31(8):861-4. PubMed ID: 1290634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
    Body JJ; Dumon JC; Gineyts E; Delmas PD
    Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.